GBP2 and metabolic dysfunction-associated steatotic liver disease: We conclude the following: (i) Cmip expression is regulated by altering its methylation, and Dnmt and Tet2 are the major enzymes involved; (ii) hypomethylation enhances Cmip expression and facilitates the development and progression of NAFLD by activating the Pparγ–CD36 signaling pathway; and (iii) Gbp2, a newly identified factor mediating Cmip and the Pparγ–Cd36 axis, is also responsible for NAFLD, indicating that Cmip and Gbp2 are new preventive and therapeutic targets for NAFLD.